Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal ketamine for acute suicidality
NL-OMON46083Phase 2Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in suicidal ideation, Suicidality and nonsuicidal self-injury (NSSI) comparing Intranasal ketamine with Intranasal midazolam active placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Jul 2018; status: withdrawn.
02
Drugs
ketamine
03
Conditions
suicidal ideationSuicidalitynonsuicidal self-injury (NSSI)
Beyond the preview
Go deeper on NL-OMON46083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46083.